OmniAb Results Presentation Deck

Active Clinical Programs and Approved Products NEW CLINICAL ENTRANT IN Q1 2023 30 25 20 15 10 5 O Number of Active Clinical Programs and Approved Products 2016 2017 2018 2019 2020 2021 2022 3/31/2023 ● New program entered the clinic in Q1 2023 SGN-BB228 (Seagen): Anti-CD228 x 4-1BB Anticalin ● • Based on dialog with partners, we see potential for approximately 3-5 new entries into clinical development for novel OmniAb- derived antibodies in 2023 ● Partner progression also showing the flexibility of our platform, with an increasing number of formats and modalities in clinical or preclinical development 7 OmniAb

View entire presentation